Interplay between lncRNAs and the PI3K/AKT signaling pathway in the progression of digestive system neoplasms (Review)
- Authors:
- Xiaoyu Zhang
- Lei Shi
- Mengzhen Xing
- Chunjing Li
- Fengjun Ma
- Yuning Ma
- Yuxia Ma
-
Affiliations: Department of Acupuncture and Massage College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250000, P.R. China, Key Laboratory of New Material Research Institute, Institute of Pharmaceutical Research, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250000, P.R. China - Published online on: November 7, 2024 https://doi.org/10.3892/ijmm.2024.5456
- Article Number: 15
-
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Gapstur SM, Drope JM, Jacobs EJ, Teras LR, McCullough ML, Douglas CE, Patel AV, Wender RC and Brawley OW: A blueprint for the primary prevention of cancer: Targeting established, modifiable risk factors. CA Cancer J Clin. 68:446–470. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Argueta EA and Moss SF: The prevention of gastric cancer by Helicobacter pylori eradication. Curr Opin Gastroenterol. 37:625–630. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Tan H and Li D: Oridonin suppresses gastric cancer SGC-7901 cell proliferation by targeting the TNF-alpha/androgen receptor/TGF-beta signalling pathway axis. J Cell Mol Med. 27:2661–2674. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Gang J, Yu M, Xin G and Tan H: Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer. BMC Cancer. 21:7912021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z and Shen F: Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 20:55732019. View Article : Google Scholar : PubMed/NCBI | |
|
Bridges MC, Daulagala AC and Kourtidis A: LNCcation: lncRNA localization and function. J Cell Biol. 220:e2020090452021. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrè F, Colantoni A and Helmer-Citterich M: Revealing protein-lncRNA interaction. Brief Bioinform. 17:106–116. 2016. View Article : Google Scholar | |
|
Peng WX, Koirala P and Mo YY: LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chi Y, Wang D, Wang J, Yu W and Yang J: Long non-coding RNA in the pathogenesis of cancers. Cells. 8:10152019. View Article : Google Scholar : PubMed/NCBI | |
|
Bach DH and Lee SK: Long noncoding RNAs in cancer cells. Cancer Lett. 419:152–166. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li LJ, Chai Y, Guo XJ, Chu SL and Zhang LS: Effects of endoplasmic reticulum stress on autophagy and apoptosis of human leukemia cells via inhibition of the PI3K/AKT/mTOR signaling pathway. Mol Med Rep. 17:7886–7892. 2018.PubMed/NCBI | |
|
Porta C, Paglino C and Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014. View Article : Google Scholar : PubMed/NCBI | |
|
Hoxhaj G and Manning BD: The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 20:74–88. 2020. View Article : Google Scholar : | |
|
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell. 170:605–635. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu F, Na L, Li Y and Chen L: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 10:542020. View Article : Google Scholar : PubMed/NCBI | |
|
Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et al: The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nelson BR, Makarewich CA, Anderson DM, Winders BR, Troupes CD, Wu F, Reese AL, McAnally JR, Chen X, Kavalali ET, et al: A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science. 351:271–275. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nakano Y, Isobe K, Kobayashi H, Kaburaki K, Isshiki T, Sakamoto S, Takai Y, Tochigi N, Mikami T, Iyoda A, et al: Clinical importance of long non-coding RNA LINC00460 expression in EGFR-mutant lung adenocarcinoma. Int J Oncol. 56:243–257. 2020. | |
|
Zhou H, Feng B, Abudoureyimu M, Lai Y, Lin X, Tian C, Huang G, Chu X and Wang R: The functional role of long non-coding RNAs and their underlying mechanisms in drug resistance of non-small cell lung cancer. Life Sci. 261:1183622020. View Article : Google Scholar : PubMed/NCBI | |
|
Hu H, Wu J, Yu X, Zhou J, Yu H and Ma L: Long non-coding RNA MALAT1 enhances the apoptosis of cardiomyocytes through autophagy inhibition by regulating TSC2-mTOR signaling. Biol Res. 52:582019. View Article : Google Scholar : PubMed/NCBI | |
|
Kang X, Kong F, Huang K, Li L, Li Z, Wang X, Zhang W and Wu X: LncRNA MIR210HG promotes proliferation and invasion of non-small cell lung cancer by upregulating methylation of CACNA2D2 promoter via binding to DNMT1. Onco Targets Ther. 12:3779–3790. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tian H, Pan J, Fang S, Zhou C, Tian H, He J, Shen W, Meng X, Jin X and Gong Z: LncRNA DPP10-AS1 promotes malignant processes through epigenetically activating its cognate gene DPP10 and predicts poor prognosis in lung cancer patients. Cancer Biol Med. 18:675–692. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ali T and Grote P: Beyond the RNA-dependent function of LncRNA genes. Elife. 9:e605832020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang CL, Zhu KP and Ma XL: Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett. 396:66–75. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mariner PD, Walters RD, Espinoza CA, Drullinger LF, Wagner SD, Kugel JF and Goodrich JA: Human Alu RNA is a modular transacting repressor of mRNA transcription during heat shock. Mol Cell. 29:499–509. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Robinson EK, Covarrubias S and Carpenter S: The how and why of lncRNA function: An innate immune perspective. Biochim Biophys Acta Gene Regul Mech. 1863:1944192020. View Article : Google Scholar : | |
|
Wan Y, Yao D, Fang F, Wang Y, Wu G and Qian Y: LncRNA WT1-AS downregulates lncRNA UCA1 to suppress non-small cell lung cancer and predicts poor survival. BMC Cancer. 21:1042021. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Huang C, He Y, Sang Z, Liu G and Dai H: Knockdown of long non-coding RNA GAS5 increases mir-23a by targeting ATG3 involved in autophagy and cell viability. Cell Physiol Biochem. 48:1723–1734. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang L, Peng X, Jin H and Liu J: Long non-coding RNA PVT1 promotes autophagy as ceRNA to target ATG3 by sponging microRNA-365 in hepatocellular carcinoma. Gene. 697:94–102. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ao R, Guan L, Wang Y and Wang JN: Silencing of COL1A2, COL6A3, and THBS2 inhibits gastric cancer cell proliferation, migration, and invasion while promoting apoptosis through the PI3k-Akt signaling pathway. J Cell Biochem. 119:4420–4434. 2018. View Article : Google Scholar | |
|
Li Z, Dong H, Li M, Wu Y, Liu Y, Zhao Y, Chen X and Ma M: Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathway. Mol Med Rep. 17:2719–2723. 2018. | |
|
Tamaskovic R, Schwill M, Nagy-Davidescu G, Jost C, Schaefer DC, Verdurmen WP, Schaefer JV, Honegger A and Plückthun A: Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk. Nat Commun. 7:116722016. View Article : Google Scholar : PubMed/NCBI | |
|
Revathidevi S and Munirajan AK: Akt in cancer: Mediator and more. Semin Cancer Biol. 59:80–91. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shariati M and Meric-Bernstam F: Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 28:977–988. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shiwarski DJ, Darr M, Telmer CA, Bruchez MP and Puthenveedu MA: PI3K class II α regulates δ-opioid receptor export from the trans-Golgi network. Mol Biol Cell. 28:2202–2219. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, Li W, Hu J, Lu C and Liu Y: PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 11:7972020. View Article : Google Scholar : PubMed/NCBI | |
|
Mayer IA and Arteaga CL: The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 67:11–28. 2016. View Article : Google Scholar | |
|
Tian L, Zhao Z, Xie L and Zhu J: MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget. 9:4886–4896. 2017. View Article : Google Scholar | |
|
Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lien EC, Dibble CC and Toker A: PI3K signaling in cancer: Beyond AKT. Curr Opin Cell Biol. 45:62–71. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
M JR and S V: BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer. Gene. 678:302–311. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Brown JS and Banerji U: Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther. 172:101–115. 2017. View Article : Google Scholar | |
|
Chai C, Song LJ, Han SY, Li XQ and Li M: MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway. CNS Neurosci Ther. 24:369–380. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Liu Z, Dong Y and Kong L: E2F2 drives glioma progression via PI3K/AKT in a PFKFB4-dependent manner. Life Sci. 276:1194122021. View Article : Google Scholar : PubMed/NCBI | |
|
Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C and Greabu M: PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects. Int J Mol Sci. 22:1732020. View Article : Google Scholar : PubMed/NCBI | |
|
Ediriweera MK, Tennekoon KH and Samarakoon SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 59:147–160. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Zhou Q, Wei Y, Da M, Zhang C, Zhong J, Liu J and Shen J: The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer. Int J Clin Exp Pathol. 12:2474–2484. 2019. | |
|
Fattahi S, Amjadi-Moheb F, Tabaripour R, Ashrafi GH and Akhavan-Niaki H: PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond. Life Sci. 262:1185132020. View Article : Google Scholar : PubMed/NCBI | |
|
Narayanankutty A: PI3K/Akt/mTOR pathway as a therapeutic target for colorectal cancer: A review of preclinical and clinical evidence. Curr Drug Targets. 20:1217–1226. 2019. View Article : Google Scholar | |
|
Wang L, Li S, Luo H, Lu Q and Yu S: PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages. J Exp Clin Cancer Res. 41:3032022. View Article : Google Scholar : PubMed/NCBI | |
|
Yang J, Qin G, Luo M, Chen J, Zhang Q, Li L, Pan L and Qin S: Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT. Cell Death Dis. 6:e18292015. View Article : Google Scholar : PubMed/NCBI | |
|
Oh S, Kim H, Nam K and Shin I: Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3β/β-catenin/survivin signaling pathway in breast cancer cells. Arch Biochem Biophys. 636:110–122. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar D, Haldar S, Gorain M, Kumar S, Mulani FA, Yadav AS, Miele L, Thulasiram HV and Kundu GC: Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway. BMC Cancer. 18:522018. View Article : Google Scholar : PubMed/NCBI | |
|
Chang CZ, Wu SC, Chang CM, Lin CL and Kwan AL: Arctigenin, a potent ingredient of arctium lappa L., induces endothelial nitric oxide synthase and attenuates subarachnoid hemorrhage-induced vasospasm through PI3K/Akt pathway in a rat model. Biomed Res Int. 2015:4902092015. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng TC, Din ZH, Su JH, Wu YJ and Liu CI: Sinulariolide suppresses cell migration and invasion by inhibiting matrix metal-loproteinase-2/-9 and urokinase through the PI3K/AKT/mTOR signaling pathway in human bladder cancer cells. Mar Drugs. 15:2382017. View Article : Google Scholar | |
|
Yu M, Qi B, Xiaoxiang W, Xu J and Liu X: Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway. Biomed Pharmacother. 90:677–685. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tan YT, Lin JF, Li T, Li JJ, Xu RH and Ju HQ: LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 41:109–120. 2021. View Article : Google Scholar | |
|
Winkle M, El-Daly SM, Fabbri M and Calin GA: Noncoding RNA therapeutics-challenges and potential solutions. Nat Rev Drug Discov. 20:629–651. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chia NY and Tan P: Molecular classification of gastric cancer. Ann Oncol. 27:763–769. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Karimi P, Islami F, Anandasabapathy S, Freedman ND and Kamangar F: Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu HT, Ma RR, Lv BB, Zhang H, Shi DB, Guo XY, Zhang GH and Gao P: LncRNA-HNF1A-AS1 functions as a competing endogenous RNA to activate PI3K/AKT signalling pathway by sponging miR-30b-3p in gastric cancer. Br J Cancer. 122:1825–1836. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dai Q, Zhang T, Pan J and Li C: LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway. J Cancer. 11:3882–3892. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Bo X, Yi X, Xiao X, Zheng Q, Ma L and Li B: Exosome-transferred LINC01559 promotes the progression of gastric cancer via PI3K/AKT signaling pathway. Cell Death Dis. 11:7232020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Q, Ma J, Wei J, Meng W, Wang Y and Shi M: FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway. Mol Oncol. 15:299–316. 2021. View Article : Google Scholar | |
|
Zhao W, Zhao X, Xu M, Cheng Z and Zhang Z: Knockdown of LINC01279 suppresses gastric cancer proliferation and migration by inhibiting PI3K/Akt/mTOR signaling pathway. J Oncol. 2022:62289822022. View Article : Google Scholar : PubMed/NCBI | |
|
Han L, Hao Y, Wang J, Wang Z, Yang H and Wu X: Knockdown of LINC02465 suppresses gastric cancer cell growth and metastasis Via PI3K/AKT pathway. Hum Gene Ther Clin Dev. 30:19–28. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng C, Qin Y, Zhi Q, Wang J and Qin C: Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 107:2620–2629. 2018. View Article : Google Scholar | |
|
Wang Q, Mao X, Luo F and Wang J: LINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathway. J Cell Mol Med. 25:9112–9127. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Y, Zhang J, Hou L, Wang G, Liu H, Zhang R, Chen X and Zhu J: LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 36:1942017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu K, Ren Q and Zhao Y: lncRNA MALAT1 overexpression promotes proliferation, migration and invasion of gastric cancer by activating the PI3K/AKT pathway. Oncol Lett. 17:5335–5342. 2019.PubMed/NCBI | |
|
Dai Q, Zhang T and Li C: LncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K/AKT pathway. Cancer Manag Res. 12:1929–1939. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Zhang Y, Ding M and Xu R: Long noncoding RNA TMPO-AS1/miR-126-5p/BRCC3 axis accelerates gastric cancer progression and angiogenesis via activating PI3K/Akt/mTOR pathway. J Gastroenterol Hepatol. 36:1877–1888. 2021. View Article : Google Scholar | |
|
Du DX, Lian DB, Amin BH and Yan W: Long non-coding RNA CRNDE is a novel tumor promoter by modulating PI3K/AKT signal pathways in human gastric cancer. Eur Rev Med Pharmacol Sci. 21:5392–5398. 2017.PubMed/NCBI | |
|
Zhuang SH, Meng CC, Fu JJ and Huang J: Long non-coding RNA ELFN1-AS1-mediated ZBTB16 inhibition augments the progression of gastric cancer by activating the PI3K/AKT axis. Kaohsiung J Med Sci. 38:621–632. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ma F, An K and Li Y: Silencing of long non-coding RNA-HCG18 inhibits the tumorigenesis of gastric cancer through blocking PI3K/Akt pathway. Onco Targets Ther. 13:2225–2234. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yao L, Ye PC, Tan W, Luo YJ, Xiang WP, Liu ZL, Fu ZM, Lu F, Tang LH and Xiao JW: Decreased expression of the long non-coding RNA HOXD-AS2 promotes gastric cancer progression by targeting HOXD8 and activating PI3K/Akt signaling pathway. World J Gastrointest Oncol. 12:1237–1254. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Yan X, Wang F, Yang Q, Luo X, Kong J and Ju S: Down-regulated lncRNA SLC25A5-AS1 facilitates cell growth and inhibits apoptosis via miR-19a-3p/PTEN/PI3K/AKT signalling pathway in gastric cancer. J Cell Mol Med. 23:2920–2932. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Liang G, Yang S, Sui J, Wu W, Xu S, Ye Y, Shen B, Zhang X and Zhang Y: LncRNA-LOC101928316 contributes to gastric cancer progression through regulating PI3K-Akt-mTOR signaling pathway. Cancer Med. 8:4428–4440. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liang LC, Liu LQ, Liu L, Liu DL, He YR, Wan X, Zhu ZQ, Zhang BG, Liu SJ, Wu H and Hu L: Long non-coding RNA BX357664 inhibits gastric cancer progression by sponging miR-183a-3p to regulate the PTEN expression and PI3K/AKT pathway. Food Chem Toxicol. 150:1120692021. View Article : Google Scholar : PubMed/NCBI | |
|
Li JF, Li WH, Xue LL and Zhang Y: Long non-coding RNA PICART1 inhibits cell proliferation by regulating the PI3K/AKT and MAPK/ERK signaling pathways in gastric cancer. Eur Rev Med Pharmacol Sci. 23:588–597. 2019.PubMed/NCBI | |
|
Cen D, Huang H, Yang L, Guo K and Zhang J: Long noncoding RNA STXBP5-AS1 inhibits cell proliferation, migration, and invasion through inhibiting the PI3K/AKT signaling pathway in gastric cancer cells. Onco Targets Ther. 12:1929–1936. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P, Zhao X, Wang H, Zheng M, Wang Q and Chang W: The down-regulation of lncRNA PCAT18 promotes the progression of gastric cancer via MiR-107/PTEN/PI3K/AKT signaling pathway. Onco Targets Ther. 12:11017–11031. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J, Wang M, Yang Y, Xing Y and Li S: LncRNA DLEU2 silencing impedes the migration, invasion and EMT in gastric cancer cell by suppressing PI3K/AKT signaling pathway. Immunopharmacol Immunotoxicol. 44:719–731. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wong MCS, Huang J, Lok V, Wang J, Fung F, Ding H and Zheng ZJ: Differences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic location. Clin Gastroenterol Hepatol. 19:955–966.e61. 2021. View Article : Google Scholar | |
|
Zhang F, Su T and Xiao M: RUNX3-regulated circRNA METTL3 inhibits colorectal cancer proliferation and metastasis via miR-107/PER3 axis. Cell Death Dis. 13:5502022. View Article : Google Scholar : PubMed/NCBI | |
|
Song W, Mei JZ and Zhang M: Long noncoding RNA PlncRNA-1 promotes colorectal cancer cell progression by regulating the PI3K/Akt signaling pathway. Oncol Res. 26:261–268. 2018. View Article : Google Scholar | |
|
Yun WK, Hu YM, Zhao CB, Yu DY and Tang JB: HCP5 promotes colon cancer development by activating AP1G1 via PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 23:2786–2793. 2019.PubMed/NCBI | |
|
Zhang X, Yi S, Xing G, Wu H, Zhu Y, Guo X and Zhang L: FOXCUT promotes the proliferation and invasion by activating FOXC1/PI3K/AKT pathway in colorectal cancer. Cancer Manag Res. 12:6269–6278. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Kuang H, Xue J, Liao L, Yin F and Zhou X: LncRNA AB073614 regulates proliferation and metastasis of colorectal cancer cells via the PI3K/AKT signaling pathway. Biomed Pharmacother. 93:1230–1237. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang P, Li J, Peng C, Tan Y, Chen R, Peng W, Gu Q, Zhou J, Wang L, Tang J, et al: TCONS_00012883 promotes proliferation and metastasis via DDX3/YY1/MMP1/PI3K-AKT axis in colorectal cancer. Clin Transl Med. 10:e2112020. View Article : Google Scholar : PubMed/NCBI | |
|
Cui Z, Han B, Wang X, Li Z, Wang J and Lv Y: Long non-coding RNA TTN-AS1 promotes the proliferation and invasion of colorectal cancer cells by activating miR-497-mediated PI3K/Akt/mTOR signaling. Onco Targets Ther. 12:11531–11539. 2019. View Article : Google Scholar | |
|
Pei Q, Liu GS, Li HP, Zhang Y, Xu XC, Gao H, Zhang W and Li T: Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 23:9871–9881. 2019.PubMed/NCBI | |
|
Duan Q, Cai L, Zheng K, Cui C, Huang R, Zheng Z, Xie L, Wu C, Yu X and Yu J: lncRNA KCNQ1OT1 knockdown inhibits colorectal cancer cell proliferation, migration and invasiveness via the PI3K/AKT pathway. Oncol Lett. 20:601–610. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang JJ, Xu WR, Chen B, Wang YY, Yang N, Wang LJ and Zhang YL: The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway. Eur Rev Med Pharmacol Sci. 23:8321–8331. 2019.PubMed/NCBI | |
|
Fang J, Yang J, Chen H, Sun W, Xiang L and Feng J: Long non-coding RNA LBX2-AS1 predicts poor survival of colon cancer patients and promotes its progression via regulating miR-627-5p/RAC1/PI3K/AKT pathway. Hum Cell. 35:1521–1534. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Feng W, Li B, Wang J, Zhang H, Liu Y, Xu D, Cheng K and Zhuang J: Long non-coding RNA LINC00115 contributes to the progression of colorectal cancer by targeting miR-489-3p via the PI3K/AKT/mTOR pathway. Front Genet. 11:5676302020. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Zeng C, Hu J, Pan Y, Shan Y, Liu B and Jia L: Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression. J Hematol Oncol. 11:892018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Pan S, Xiao Y, Liu Q, Xu J and Jia L: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway. J Exp Clin Cancer Res. 37:3162018. View Article : Google Scholar : PubMed/NCBI | |
|
Lei Y, Wang YH, Wang XF and Bai J: LINC00657 promotes the development of colon cancer by activating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 25:24602021.PubMed/NCBI | |
|
Meng S, Jian Z, Yan X, Li J and Zhang R: LncRNA SNHG6 inhibits cell proliferation and metastasis by targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer. Mol Med Rep. 20:2541–2548. 2019.PubMed/NCBI | |
|
Hu J, Shan Y, Ma J, Pan Y, Zhou H, Jiang L and Jia L: LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α-2,3 sialylation via PI3K/Akt signaling. Int J Cancer. 145:450–460. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hao B, Wen H, Sun Y, Le Z, Zhang Z, Liu M and Hu T: LncRNA-CASC7 inhibits the proliferation and migration of colon cancer by negatively regulating the PI3K/Akt signaling pathway. J Gastrointest Oncol. 12:2803–2813. 2021. View Article : Google Scholar | |
|
Zhang H, Zhang G, Liu H, Shan Y and Zhang X: RP11-462C24.1 suppresses proliferation and invasion of colorectal carcinoma cells by regulating HSP70 through PI3K/AKT signaling pathway. Hum Cell. 34:132–151. 2021. View Article : Google Scholar | |
|
Mattiuzzi C and Lippi G: Current cancer epidemiology. J Epidemiol Glob Health. 9:217–222. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng K, Cai N, Zhu J, Yang X, Liang H and Zhang W: Tumor-associated macrophages in liver cancer: From mechanisms to therapy. Cancer Commun (Lond). 42:1112–1140. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Han K, Li C, Zhang X and Shang L: DUXAP10 inhibition attenuates the proliferation and metastasis of hepatocellular carcinoma cells by regulation of the Wnt/β-catenin and PI3K/Akt signaling pathways. Biosci Rep. 39:BSR201814572019. View Article : Google Scholar | |
|
Zhuang J, He S, Wang G, Wang G, Ni J, Zhang S, Ye Y and Xia W: Long noncoding RNA FGFR3-AS1 promotes hepatocellular carcinoma carcinogenesis via modulating the PI3K/AKT pathway. Oncol Res. 26:1257–1265. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng YF, Zhang XY and Bu YZ: LINC01133 aggravates the progression of hepatocellular carcinoma by activating the PI3K/AKT pathway. J Cell Biochem. 120:4172–4179. 2019. View Article : Google Scholar | |
|
Han Y, Chen M, Wang A and Fan X: STAT3-induced upregulation of lncRNA CASC11 promotes the cell migration, invasion and epithelial-mesenchymal transition in hepatocellular carcinoma by epigenetically silencing PTEN and activating PI3K/AKT signaling pathway. Biochem Biophys Res Commun. 508:472–479. 2019. View Article : Google Scholar | |
|
Yue H, Wu K, Liu K, Gou L, Huang A and Tang H: LINC02154 promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing SPC24 promoter activity and activating the PI3K-AKT signaling pathway. Cell Oncol (Dordr). 45:447–462. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Zhou ZY, He CC, Zhang JL, Wang J and Xiao ZY: Down-regulation of LncRNA NR027113 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 22:7222–7232. 2018.PubMed/NCBI | |
|
Song XZ, Ren XN, Xu XJ, Ruan XX, Wang YL and Yao TT: LncRNA RHPN1-AS1 promotes cell proliferation, migration and invasion through targeting miR-7-5p and activating PI3K/AKT/mTOR pathway in hepatocellular carcinoma. Technol Cancer Res Treat. 19:15330338209570232020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Liang F, Li Q, Sun H, Li F, Jiao Z and Lei J: LncRNA MIR205HG accelerates cell proliferation, migration and invasion in hepatoblastoma through the activation of MAPK signaling pathway and PI3K/AKT signaling pathway. Biol Direct. 17:22022. View Article : Google Scholar : PubMed/NCBI | |
|
Huang JL, Cao SW, Ou QS, Yang B, Zheng SH, Tang J, Chen J, Hu YW, Zheng L and Wang Q: The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol Cancer. 17:932018. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Q, Zheng X and Zhang J: Long non-coding RNA CRNDE promotes heptaocellular carcinoma cell proliferation by regulating PI3K/Akt/β-catenin signaling. Biomed Pharmacother. 103:1187–1193. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Song Q, Zhang H, He J, Kong H, Tao R, Huang Y, Yu H, Zhang Z, Huang Z, Wei L, et al: Long non-coding RNA LINC00473 acts as a microRNA-29a-3p sponge to promote hepatocellular carcinoma development by activating Robo1-dependent PI3K/AKT/mTOR signaling pathway. Ther Adv Med Oncol. 12:17588359209378902020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu JH, Tian XY, An QM, Guan XY and Hao CY: LINC00963 promotes hepatocellular carcinoma progression by activating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 22:1645–1652. 2018.PubMed/NCBI | |
|
Hou Y, Chen K, Liao R, Li Y, Yang H and Gong J: LINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathway. Lab Invest. 101:570–587. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong F, Liu S, Hu D and Chen L: LncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosis. J Cancer. 13:1048–1060. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Shen Q, Jiang S, Wu M, Zhang L, Su X and Zhao D: LncRNA HEIH confers cell sorafenib resistance in hepatocellular carcinoma by regulating miR-98-5p/PI3K/AKT pathway. Cancer Manag Res. 12:6585–6595. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Peng N, He J, Li J, Huang H, Huang W, Liao Y and Zhu S: Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell Int. 20:1652020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou W, Wang J, Zhang J, Wang Y, Jiang L, Guo T, Luo B, Xu Q and Huang Y: LncRNA NCK1-AS1 aggravates hepatocellular carcinoma by the miR-22-3p/YARS axis to activate PI3K/AKT signaling. J Gastrointestin Liver Dis. 31:48–59. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ma ZJ, Wang Y, Li HF, Liu MH, Bi FR, Ma L, Ma H and Yan HL: LncZEB1-AS1 regulates hepatocellular carcinoma bone metastasis via regulation of the miR-302b-EGFR-PI3K-AKT axis. J Cancer. 11:5118–5128. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Qi Y, Huang Y, Guo Y, Huang T and Jia L: Exosome-derived SNHG16 sponging miR-4500 activates HUVEC angiogenesis by targeting GALNT1 via PI3K/Akt/mTOR pathway in hepatocellular carcinoma. J Physiol Biochem. 77:667–682. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Dong K, Jin Q, Ma Y, Yin S and Wang S: Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway. J Cell Biochem. 120:6781–6788. 2019. View Article : Google Scholar | |
|
Sun L, Zhou J and Sun C: MicroRNA-211-5p enhances analgesic effect of dexmedetomidine on inflammatory visceral pain in rats by suppressing ERK signaling. J Mol Neurosci. 68:19–28. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Luo LH, Jin M, Wang LQ, Xu GJ, Lin ZY, Yu DD, Yang SL, Ran RZ, Wu G and Zhang T: Long noncoding RNA TCL6 binds to miR-106a-5p to regulate hepatocellular carcinoma cells through PI3K/AKT signaling pathway. J Cell Physiol. 235:6154–6166. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wolpin BM: Pancreatic cancer. Hematol Oncol Clin North Am. 29:13–14. 2015. View Article : Google Scholar | |
|
Zhao Z and Liu W: Pancreatic cancer: A review of risk factors, diagnosis, and treatment. Technol Cancer Res Treat. 19:15330338209621172020. View Article : Google Scholar : PubMed/NCBI | |
|
Luo C, Lin K, Hu C, Zhu X, Zhu J and Zhu Z: LINC01094 promotes pancreatic cancer progression by sponging miR-577 to regulate LIN28B expression and the PI3K/AKT pathway. Mol Ther Nucleic Acids. 26:523–535. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Qiao X, Lv SX, Qiao Y, Li QP, Ye B, Wang CC and Miao L: Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 22:8630–8639. 2018.PubMed/NCBI | |
|
Zhang Y, Zhang R, Luo G and Ai K: Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma. J Cancer. 9:2713–2722. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gu L, Zhang J, Shi M, Zhan Q, Shen B and Peng C: lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity. Biomed Pharmacother. 89:1269–1276. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H and Ajani JA: Recent advances in treating oesophageal cancer. F1000Res. 9:F1000 Faculty Rev-11892020. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Yang B, Ma Y, Peng X, Wang Z, Sheng B, Wei Z, Cui Y and Liu Z: Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma. Signal Transduct Target Ther. 6:3812021. View Article : Google Scholar : PubMed/NCBI | |
|
Reichenbach ZW, Murray MG, Saxena R, Farkas D, Karassik EG, Klochkova A, Patel K, Tice C, Hall TM, Gang J, et al: Clinical and translational advances in esophageal squamous cell carcinoma. Adv Cancer Res. 144:95–135. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Ma J, Guan B, Li J, Wang Y and Hu S: LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling. Cell Cycle. 20:1374–1388. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Sun J, Zhao H and Li H: Long non-coding RNA (lncRNA) growth arrest specific 5 (GAS5) suppresses esophageal squamous cell carcinoma cell proliferation and migration by inactivating phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. Med Sci Monit. 24:7689–7696. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fu X, Cui G, Liu S and Zhao S: Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR-PI3K-AKT-mTOR signalling pathway. J Cell Mol Med. 24:1670–1675. 2020. View Article : Google Scholar | |
|
Baiu I and Visser B: Gallbladder cancer. JAMA. 320:12942018. View Article : Google Scholar : PubMed/NCBI | |
|
Hickman L and Contreras C: Gallbladder cancer: Diagnosis, surgical management, and adjuvant therapies. Surg Clin North Am. 99:337–355. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Roa JC, García P, Kapoor VK, Maithel SK, Javle M and Koshiol J: Gallbladder cancer. Nat Rev Dis Primers. 8:692022. View Article : Google Scholar : PubMed/NCBI | |
|
Wei CX, Wong H, Xu F, Liu Z, Ran L and Jiang RD: IRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signaling. Eur Rev Med Pharmacol Sci. 22:8169–8178. 2018.PubMed/NCBI | |
|
Wang C, Mao ZP, Wang L, Wu GH, Zhang FH, Wang DY and Shi JL: Long non-coding RNA MALAT1 promotes cholangiocarcinoma cell proliferation and invasion by activating PI3K/Akt pathway. Neoplasma. 64:725–731. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Zhang L, Lu S, Xiang Y, Zeng C, He T, Ding Y and Wang W: Long non-coding RNA CASC15 promotes intrahepatic cholangiocarcinoma possibly through Inducing PRDX2/PI3K/AKT axis. Cancer Res Treat. 53:184–198. 2021. View Article : Google Scholar : | |
|
Cai Q, Wang ZQ, Wang SH, Li C, Zhu ZG, Quan ZW and Zhang WJ: Upregulation of long non-coding RNA LINC00152 by SP1 contributes to gallbladder cancer cell growth and tumor metastasis via PI3K/AKT pathway. Am J Transl Res. 8:4068–4081. 2016.PubMed/NCBI | |
|
Cheung PK, Ma MH, Tse HF, Yeung KF, Tsang HF, Chu MKM, Kan CM, Cho WCS, Ng LBW, Chan LWC and Wong SCC: The applications of metabolomics in the molecular diagnostics of cancer. Expert Rev Mol Diagn. 19:785–793. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu L and Qu X: Cancer biomarker detection: Recent achievements and challenges. Chem Soc Rev. 44:2963–2997. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Goyal B, Yadav SRM, Awasthee N, Gupta S, Kunnumakkara AB and Gupta SC: Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. Biochim Biophys Acta Rev Cancer. 1875:1885022021. View Article : Google Scholar : PubMed/NCBI | |
|
Nemeth K, Bayraktar R, Ferracin M and Calin GA: Non-coding RNAs in disease: From mechanisms to therapeutics. Nat Rev Genet. 25:211–232. 2024. View Article : Google Scholar | |
|
Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ, Kraft P, Laden F, Mucci L, Parmigiani G, et al: Precision prevention and early detection of cancer: Fundamental principles. Cancer Discov. 8:803–811. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Borrebaeck CAK: Precision diagnostics: Moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer. 17:199–204. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xia M, Zhu W, Tao C, Lu Y and Gao F: LncRNA LASTR promote lung cancer progression through the miR-137/TGFA/PI3K/ AKT axis through integration analysis. J Cancer. 13:1086–1096. 2022. View Article : Google Scholar : | |
|
Xu D, Yu J, Zhuang S, Zhang S, Hong Z and Yuan C: Overexpression of long non-coding RNA LINC00982 suppresses cell proliferation and tumor growth of papillary thyroid carcinoma through PI3K-ATK signaling pathway. Biosci Rep. 39:BSR201912102019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu ZB, Wang JA and Lv RQ: Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis. Eur Rev Med Pharmacol Sci. 23:1418–1427. 2019.PubMed/NCBI | |
|
Ma L, Kuai WX, Sun XZ, Lu XC and Yuan YF: Long noncoding RNA LINC00265 predicts the prognosis of acute myeloid leukemia patients and functions as a promoter by activating PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 22:7867–7876. 2018.PubMed/NCBI | |
|
Gao XF, He HQ, Zhu XB, Xie SL and Cao Y: LncRNA SNHG20 promotes tumorigenesis and cancer stemness in glioblastoma via activating PI3K/Akt/mTOR signaling pathway. Neoplasma. 66:532–542. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Feng S and Chen L: MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway. Mol Cell Biochem. 476:699–713. 2021. View Article : Google Scholar : | |
|
Zhou J, Xu N, Liu B, Wang C, He Z, Lenahan C, Tang W, Zeng H and Guo H: lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma. Cancer Sci. 113:2681–2692. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Niu W, Mu M, Hu S and Niu C: Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop. J Exp Clin Cancer Res. 39:1962020. View Article : Google Scholar : PubMed/NCBI | |
|
Swain SM, Shastry M and Hamilton E: Targeting HER2-positive breast cancer: Advances and future directions. Nat Rev Drug Discov. 22:101–126. 2023. View Article : Google Scholar | |
|
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, et al: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 401:105–117. 2023. View Article : Google Scholar | |
|
Liu J, Chen M, Ma L, Dang X and Du G: LncRNA GAS5 suppresses the proliferation and invasion of osteosarcoma cells via the miR-23a-3p/PTEN/PI3K/AKT pathway. Cell Transplant. 29:9636897209530932020. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Tan H and Gang J: Inhibition of hepatocellular carcinoma cell proliferation through regulation of the Cell Cycle, AGE-RAGE, and Leptin signaling pathways by a compound formulation comprised of andrographolide, wogonin, and oroxylin A derived from Andrographis Paniculata(Burm.f.) Nees. J Ethnopharmacol. 329:1180012024. View Article : Google Scholar | |
|
Gourd K: ESMO gastrointestinal cancers congress 2024. Lancet Oncol. 25:9612024. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, et al: Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 50:1705–1715. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cantile M, Di Bonito M, Cerrone M, Collina F, De Laurentiis M and Botti G: Long non-coding RNA HOTAIR in breast cancer therapy. Cancers (Basel). 12:11972020. View Article : Google Scholar : PubMed/NCBI | |
|
Bhat AA, Afzal O, Afzal M, Gupta G, Thapa R, Ali H, Hassan Almalki W, Kazmi I, Alzarea SI, Saleem S, et al: MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting. Pathol Res Pract. 253:1549912024. View Article : Google Scholar | |
|
Loewen G, Jayawickramarajah J, Zhuo Y and Shan B: Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol. 7:902014. View Article : Google Scholar : PubMed/NCBI | |
|
Nanni S, Aiello A, Salis C, Re A, Cencioni C, Bacci L, Pierconti F, Pinto F, Ripoli C, Ostano P, et al: Metabolic reprogramming by Malat1 depletion in prostate cancer. Cancers (Basel). 13:152020. View Article : Google Scholar : PubMed/NCBI | |
|
Li T, Liu N, Gao Y, Quan Z, Hao Y, Yu C, Li L, Yuan M, Niu L, Luo C and Wu X: Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM. Br J Cancer. 124:247–258. 2021. View Article : Google Scholar : |
